Loading...

Prodrugs and Targeted Delivery: Towards Better ADME Properties

Description
By definition, drugs are highly active substances that are beneficial if they act at the right time and in the right place, but can cause harm otherwise. A clever strategy to ensure that a drug only becomes active when needed is to "camouflage" it. Such camouflaged, i.e. deactivated, drugs that become chemically or biochemically activated once they reach their site of action are called prodrugs.

This topical reference and handbook addresses the chemistry, pharmacology, toxicology and the patentability of prodrugs, perfectly mirroring the integrated approach prevalent in today's drug design. It summarizes current experiences and strategies, beginning at the early stages of the development process, while also discussing organ- and site-selective prodrugs.

From the contents:
* Prodrug design and intellectual property
* Prodrugs addressing ADMET issues
* Codrugs and soft drugs
* Preclinical and clinical consideration for prodrugs

This book is a valuable reference for all companies employing medicinal chemists by giving a practice-oriented overview of a key strategy in modern drug discovery and development.
About the Author
Jarkko Rautio is professor of pharmaceutical chemistry and head of the multidisciplinary Pharmaceutical and Medicinal Chemistry (PMC) research group at the School of Pharmacy, University of Eastern Finland (formerly University of Kuopio), where he received his PhD in pharmaceutical chemistry in 2000. He subsequently carried out his postdoctoral studies at the University of Maryland, Baltimore, USA, and was a visiting scientist at GlaxoSmithKline, North Carolina, while also co-founding the American Association of Pharmaceutical Scientists (AAPS) Prodrug Focus Group in 2005. Professor Rautio's research focuses on chemistry-based methods, especially prodrugs, to overcome the liabilities of drugs.